Subscribe
shutterstock_1653845269_taljat_david
Taljat David / Shutterstock.com
12 May 2022Big PharmaAlex Baldwin

Novartis' Gilenya patent survives invalidity bid

Novartis has convinced a Delaware court that a patent for its flagship multiple sclerosis treatment Gilenya (fingolimod) is directed at patent-eligible matter, dismissing a challenge from Handa Pharmaceuticals that the patent is directed at natural phenomena and invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Novartis sued over blockbuster heart failure drug
30 August 2022   Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.
Americas
Novartis, Dana-Farber seek to bar generic leukaemia drug
9 June 2022   Novartis Pharmaceuticals and the Dana-Farber Cancer Institute have filed two lawsuits to bar generic versions of leukaemia drug, Rydapt.
Big Pharma
Roche asks court for halt of Novartis unit’s generic launch
4 April 2022   Roche’s subsidiary Genentech has asked a Delaware court to block two of Novartis’ units from selling a generic version of the blockbuster lung-disease drug Esbriet.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Generics
Novartis sued over blockbuster heart failure drug
30 August 2022   Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.
Americas
Novartis, Dana-Farber seek to bar generic leukaemia drug
9 June 2022   Novartis Pharmaceuticals and the Dana-Farber Cancer Institute have filed two lawsuits to bar generic versions of leukaemia drug, Rydapt.
Big Pharma
Roche asks court for halt of Novartis unit’s generic launch
4 April 2022   Roche’s subsidiary Genentech has asked a Delaware court to block two of Novartis’ units from selling a generic version of the blockbuster lung-disease drug Esbriet.

More on this story

Generics
Novartis sued over blockbuster heart failure drug
30 August 2022   Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.
Americas
Novartis, Dana-Farber seek to bar generic leukaemia drug
9 June 2022   Novartis Pharmaceuticals and the Dana-Farber Cancer Institute have filed two lawsuits to bar generic versions of leukaemia drug, Rydapt.
Big Pharma
Roche asks court for halt of Novartis unit’s generic launch
4 April 2022   Roche’s subsidiary Genentech has asked a Delaware court to block two of Novartis’ units from selling a generic version of the blockbuster lung-disease drug Esbriet.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB